IDEXX Laboratories Shares Rise 2.57% as Q3 Earnings Beat Forecasts and FY2026 Guidance Increases
IDEXX Laboratories (IDXX) shares rose 2.57% after Q3 2026 earnings beat estimates with $3.96 EPS vs. $3.72 expected. Revenue grew 10% to $1.21B, surpassing forecasts. The company raised FY2026 guidance, targeting $4.74B–$4.77B in revenue and $14.96–$15.16 in EPS. Growth was driven by increased demand for diagnostic products and services, with CAG Diagnostics recurring revenue up 11%.
How this was made
The 30-second read
Why it matters
The earnings beat and guidance lift suggest continued demand for veterinary diagnostics, supporting higher valuations.
Market read
Earnings beat and guidance raise provide a clear catalyst for IDXX and may influence related health‑care stocks.
What to watch
Potential supply‑chain constraints for consumables or slower adoption of new instruments could temper growth.
Background
IDEXX is a leading provider of veterinary diagnostic equipment and consumables, with recurring revenue from its Companion Animal Group.
Ticker impact
IDEXX reported Q3 earnings beat and raised FY2026 revenue and EPS guidance, driving a 2.57% pre‑market share rise.
upward pressure as investors price in higher revenue and earnings outlook
Earnings beat of $3.96 vs $3.72 and guidance lift to $4.74‑$4.77B revenue and $14.96‑$15.16 EPS provide fresh, material information.
Market effects
Strong veterinary diagnostics results may boost sentiment for health‑care and animal‑care stocks.
U.S. market participants may see a modest lift in the health‑care sector.
Limited to U.S. listed health‑care and specialty diagnostics peers.
Counterpoint
If the guidance raise is already priced in, the stock could face a short‑term pullback.
Key entities
- ExecutiveMike Erickson
CEO who highlighted innovation‑driven growth.
